We reported positive initial clinical results from our Phase 1/2 trial of ALN-CC5, an investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases. The new clinical data are being presented at the 20th
Congress of the European Hematology Association (EHA) held June 11 – 14, 2015. Initial study results from 12 healthy volunteer subjects showed that subcutaneous administration of a single dose of ALN-CC5 resulted in potent, dose-dependent, durable, and statistically significant knockdown of serum C5 of up to 96%. In addition, single dose administration of ALN-CC5 achieved inhibition of serum complement activity of up to 92%, including an up to 61% inhibition of serum hemolytic activity. Further, ALN-CC5 has been found to be generally well tolerated to date.
[spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=917666" type=" "] Read our press release[/spotlight-link]
[spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/ALN-CC5-EHA2015_FINAL.pdf" type="(677 KB PDF)"] View our presentation[/spotlight-link]